02/22
Headlines

INSY

Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Jason Knox03 mins

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and…

Read More

NASDAQ Insider Buying: Prospect Capital (NASDAQ:PSEC), CyrusOne (NASDAQ:CONE), National Penn Bancshares (NASDAQ:NPBC), Insys Therapeutics (NASDAQ:INSY), Bank Of The Ozarks (NASDAQ:OZRK)

Jayne Crisman03 mins

Prospect Capital Corp. (NASDAQ:PSEC) CEO John F. Barry purchased 100,000 shares of the stock in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $10.37 per share, for a total transaction of $1,037,000.00. Following the completion of the purchase, the chief executive officeronline.wsj.comchief executive officer now directly owns 4,110,959…

Read More

Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Mark DeFrance03 mins

Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million…

Read More

Biotech Volatile Stocks: Lexicon Pharmaceuticals (NASDAQ:LXRX), Corcept Therapeutics Incorporated (NASDAQ:CORT), Insys Therapeutics (NASDAQ:INSY), ANI Pharmaceuticals (NASDAQ:ANIP)

Colin Pettis02 mins

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), just announced a positive, top-line result in a Phase 2 clinical trial of their experimental therapy LX4211 in type 1 diabetes. LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, was designed to lower blood glucose levels through two insulin-independent mechanisms of action. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)…

Read More
Gilead Sciences GILD NASDAQ:GILD

Biotech Bullish Stocks: Regulus Therapeutics Inc (NASDAQ:RGLS), Insys Therapeutics (NASDAQ:INSY), Repligen Corporation (NASDAQ:RGEN), Sarepta Therapeutics (NASDAQ:SRPT)

Kevin Long02 mins

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) were the target of a significant decrease in short interest in January. As of March 14th, there was short interest totaling 1,460,571 shares, a decrease of 20.3% from the February 28th total of 1,832,140 shares, Analyst Ratings Newsreports. Regulus Therapeutics Inc (NASDAQ:RGLS) stock performance was 5.09% in last session…

Read More

Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

Richard Atkins02 mins

The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”) of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock performance was -5.40% in last session…

Read More